Nanotechnology drug delivery systems involve the engineering of functional systems at the molecular scale, characterized by unique physical, optical and electronic features. Nanomedicine is a highly specific medical intervention for the prevention, diagnosis and treatment of diseases. Several anti-cancer drugs including paclitaxel, doxorubicin, 5-fluorouracil and dexamethasone have been successfully formulated using nanomaterials. Quantom dots, chitosan, Polylactic or glycolic acid (PLGA) and PLGA-based nanoparticles have also been used for in vitro RNAi delivery. The ability of nanotechnology to provide targeted drug delivery, improved solubility, extended half-life and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. Over the last two decades, significant progress has been made in the field of nanomedicine, resulting in a number of products, including therapeutics and imaging agents, enabling more effective and less toxic therapeutic and diagnostic interventions
The global nanotechnology drug delivery systems market segmentation is based on technology types (nanocrystals, nanoparticles, dendrimers, gold nanoparticles, fullerenes, liposomes, micelles, nanotubes), and its applications (anti-infective, anti-inflammatory, immunology, cardiovascular, physiology, neurology, oncology). The global nanotechnology drug delivery systems market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global nanotechnology drug delivery systems market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nanotechnology drug delivery systems market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nanotechnology drug delivery systems market and included in this report are AbbVie, Amgen, Celgene Corporation, Elan Pharmaceuticals, Johnson & Johnson, Pfizer, Inc., Merck & Co., Novartis AG, and Teva Pharmaceuticals.